Generic Jornay PM Availability
Last updated on Apr 10, 2025.
Jornay PM is a brand name of methylphenidate, approved by the FDA in the following formulation(s):
JORNAY PM (methylphenidate hydrochloride - capsule, extended release;oral)
-
Manufacturer: IRONSHORE PHARMS
Approval date: August 8, 2018
Strength(s): 20MG [RLD], 40MG [RLD], 60MG [RLD], 80MG [RLD], 100MG [RLD]
Is there a generic version of Jornay PM available?
No. There is currently no therapeutically equivalent version of Jornay PM available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jornay PM. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 10,182,995
Issued: January 22, 2019
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Methods of treatment of attention deficit hyperactivity disorder
Patent 10,292,937
Issued: May 21, 2019
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 7 hours or longer, followed by an ascending release rate. When administered at night the composition provides early morning improvement in symptoms of ADHD and sustained improvement over a period of at least 12 hours.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 10,617,651
Issued: April 14, 2020
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 10,881,618
Issued: January 5, 2021
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): Ironshore Pharmaceuticals & Development, Inc.Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 10,905,652
Issued: February 2, 2021
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): Ironshore Pharmaceuticals & Development, Inc.Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 11,241,391
Issued: February 8, 2022
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 11,241,392
Issued: February 8, 2022
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 11,911,518
Issued: February 27, 2024
Inventor(s): Lickrish; David et al.
Assignee(s): Ironshore Pharmaceuticals & Development, Inc. (Camana Bay, KY)Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Methods for treatment of attention deficit hyperactivity disorder
Patent 8,916,588
Issued: December 23, 2014
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): Ironshore Pharmaceuticals & Development, Inc.Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 8,927,010
Issued: January 6, 2015
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): Ironshore Pharmaceuticals & Development, Inc.Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 9,023,389
Issued: May 5, 2015
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): Ironshore Pharmaceuticals & Development, Inc.Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Methods and compositions for treatment of attention deficit disorder
Patent 9,028,868
Issued: May 12, 2015
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): Ironshore Pharmaceuticals & Development, Inc.Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 3 to 8 hours, followed by an ascending release rate.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Methods for treatment of attention deficit hyperactivity disorder
Patent 9,034,902
Issued: May 19, 2015
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): Ironshore Pharmaceuticals & Development, Inc.Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 9,283,214
Issued: March 15, 2016
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): Ironshore Pharmaceuticals & Development, Inc.Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Compositions for treatment of attention deficit hyperactivity disorder
Patent 9,498,447
Issued: November 22, 2016
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): Ironshore Pharmaceuticals & Development, Inc.Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
-
Methods of treatment of attention deficit hyperactivity disorder
Patent 9,603,809
Issued: March 28, 2017
Inventor(s): Lickrish David & Zhang Feng
Assignee(s): Ironshore Pharmaceuticals & Development, Inc.Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 7 hours or longer, followed by an ascending release rate. When administered at night the composition provides early morning improvement in symptoms of ADHD and sustained improvement over a period of at least 12 hours.
Patent expiration dates:
- March 23, 2032✓
- March 23, 2032
More about Jornay PM (methylphenidate)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (18)
- Drug images
- Latest FDA alerts (4)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CNS stimulants
- Breastfeeding
- En español
Patient resources
Other brands
Concerta, Ritalin, Ritalin LA, Daytrana, ... +9 more
Professional resources
Other brands
Concerta, Ritalin, Ritalin LA, Daytrana, ... +9 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
